What is the empiric treatment for suspected heart failure with unknown ejection fraction?

Empiric Treatment for Suspected Heart Failure with Unknown Ejection Fraction

Start diuretics immediately if signs or symptoms of congestion are present, and obtain urgent transthoracic echocardiography (TTE) to determine ejection fraction before initiating disease-modifying therapies. 1

Immediate Management Approach

Step 1: Assess for Congestion and Initiate Symptomatic Relief

• Diuretics should be started immediately if the patient has signs (pulmonary crackles, peripheral edema, elevated jugular venous pressure) or symptoms (dyspnea, orthopnea) of volume overload 1
• This is a Class I, Level B recommendation that improves symptoms and exercise capacity regardless of ejection fraction
• Do NOT wait for echocardiography to start diuretics in congested patients

Step 2: Obtain Urgent Echocardiography

• TTE is the essential diagnostic test (Class I, Level C recommendation) to establish whether the patient has HFrEF (EF ≤40%), HFmrEF (EF 41-49%), or HFpEF (EF ≥50%) 1
• This determination is critical because disease-modifying therapies differ dramatically based on ejection fraction
• If TTE cannot be obtained rapidly, measure B-type natriuretic peptides to improve diagnostic accuracy while awaiting imaging 2

Step 3: Avoid Harmful Medications While Awaiting EF Determination

Do NOT start the following medications empirically:

• Diltiazem or verapamil - these are Class III (harmful) recommendations in HFrEF as they increase heart failure worsening and hospitalization 1
• These calcium channel blockers could be catastrophic if the patient has reduced ejection fraction

Treatment Algorithm Once EF is Known

If HFrEF (EF ≤40%): The "Fantastic Four" Approach

All four medication classes should be initiated rapidly and simultaneously (not sequentially) 3, 4, 5:

1. ACE inhibitor (or sacubitril/valsartan can be considered as initial therapy) - Class I, Level A 1, 3
2. Beta-blocker - Class I, Level A 1
3. Mineralocorticoid receptor antagonist (MRA) - Class I, Level A 1
4. SGLT2 inhibitor (dapagliflozin or empagliflozin) - initiated regardless of diabetes status 2, 3, 4

These four pillars reduce mortality and hospitalization rates and should be up-titrated rapidly 3, 4.

If HFpEF (EF ≥50%): Comorbidity-Targeted Strategy

Treatment remains more empiric but focuses on:

• SGLT2 inhibitors - now have the strongest evidence for disease modification in HFpEF 6
• Diuretics for congestion management 1
• Blood pressure control - aggressive treatment of hypertension (Class I, Level A) 1, 7, 8
• GLP-1 receptor agonists if obese or diabetic 6
• Non-steroidal MRAs in selected patients 6

The evidence base for HFpEF is less robust than HFrEF, and treatment has historically been empiric focusing on symptom relief and comorbidity management 7, 8, 9.

If HFmrEF (EF 41-49%): Extrapolate from HFrEF

Most HFrEF treatment recommendations can be extrapolated to HFmrEF, though the evidence is not as strong 3.

Critical Pitfalls to Avoid

1. Do not delay echocardiography - empiric treatment beyond diuretics and supportive care is inappropriate without knowing EF
2. Do not use non-dihydropyridine calcium channel blockers empirically - they are contraindicated in HFrEF
3. Do not combine ACE inhibitor + ARB + MRA - this triple combination increases risk of renal dysfunction and hyperkalemia (Class III recommendation) 1
4. Do not wait to start all four pillars sequentially in HFrEF - modern approach emphasizes rapid, simultaneous initiation 3, 4

Additional Considerations

• Treat underlying hypertension aggressively regardless of EF type (Class I, Level A) 1
• Maintain sinus rhythm when possible, especially in HFpEF where atrial contraction is crucial 7, 8
• Screen for and treat iron deficiency in HFrEF patients 4
• Consider multidisciplinary heart failure disease management programs to facilitate implementation of evidence-based therapies 2